Katie Kazem

Cooley advised Valneva, a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs, on a debt facility for up to $500 million in nondilutive financing with funds managed by Pharmakon Advisors.

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.

Cooley advised AvePoint, the largest data management solutions provider for the Microsoft cloud, on its agreement to combine with Apex Technology Acquisition Corporation, a publicly traded special purpose acquisition company or SPAC. Partners David Silverman, John McKenna and Brian Leaf led the Cooley team advising AvePoint.

Cooley advised Landos Biopharma on its $100 million initial public offering of 6,250,000 shares of common stock. Landos Biopharma, whose securities now trade on the Nasdaq Global Select Market under the symbol LABP, is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases. Partners Eric Blanchard, Madison Jones and Div Gupta led the Cooley team.